SCHEMBL12091706

SCHEMBL12091706

O=C(O)Cc1c(-c2ccccc2)n(-c2ccccc2)c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IL1R1 P14778 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.60
▸ ABCB1 P08183 3/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ PLA2G2A P14555 1/20 0.50
▸ FOLH1 Q04609 1/20 0.50
▸ EGFR P00533 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.47
▸ ATM Q13315 1/20 0.47
▸ LCK P06239 1/20 0.47
▸ PRKACA P17612 1/20 0.47
▸ CSNK2A2 P19784 1/20 0.47
▸ PRKACG P22612 1/20 0.47
▸ PRKACB P22694 1/20 0.47
▸ GSK3B P49841 1/20 0.47
▸ CSNK2B P67870 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1077038 0.91 ABCB1 (0.55) IL1R1ALDH1A1ABCB1L3MBTL1KMT2A
SCHEMBL12091851 0.87 ABCB1 (0.51) IL1R1ALDH1A1ABCB1L3MBTL1KMT2A
SCHEMBL12091715 0.85 IL1R1 (0.67) IL1R1ALDH1A1ABCB1L3MBTL1KMT2A
SCHEMBL12091723 0.82 IL1R1 (0.63) IL1R1ALDH1A1ABCB1L3MBTL1KMT2A
SCHEMBL12091798 0.81 ALDH1A1 (0.66) ALDH1A1ABCB1L3MBTL1MAPTHTT
SCHEMBL1077253 0.80 IL1R1 (0.53) IL1R1ALDH1A1ABCB1L3MBTL1KMT2A
SCHEMBL8451877 0.79 ABCB1 (0.60) IL1R1ALDH1A1ABCB1L3MBTL1PLA2G2A
SCHEMBL12091703 0.78 AGTR1 (0.65) IL1R1ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL5662375 0.77 IL1R1 (0.68) IL1R1ALDH1A1ABCB1L3MBTL1KMT2A
SCHEMBL15289674 0.76 IL1R1 (1.00) IL1R1ALDH1A1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 — — US disclosed
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 — — US disclosed
US-9034871-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-05-19 — — US disclosed
US-9034871-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-05-19 — — US disclosed
EP-1809601-B1 COMPOUNDS FOR ALZHEIMER'S DISEASE MANFREDI JOHN (US) 2014-09-10 — — EP disclosed
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MYREXIS, INC. (US) 2012-09-06 — — US disclosed
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MYREXIS, INC. (US) 2012-09-06 — — US disclosed
US-20120225845-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYREXIS, INC. (US) 2012-09-06 — — US disclosed
US-20120225845-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYREXIS, INC. (US) 2012-09-06 — — US disclosed
US-20100184975-A1 COMPOUNDS FOR ALZHEIMBER'S DISEASE MYRIAD PHARMACEUTICALS, INC. (US) 2010-07-22 — — US disclosed
US-20100184975-A1 COMPOUNDS FOR ALZHEIMBER'S DISEASE MYRIAD PHARMACEUTICALS, INC. (US) 2010-07-22 — — US disclosed
US-7678823-B2 N-phenylindoles; oral dosage forms; side effect reduction Myriad Pharmaceticals, Inc. (US) 2010-03-16 — — US disclosed
US-7678823-B2 N-phenylindoles; oral dosage forms; side effect reduction Myriad Pharmaceticals, Inc. (US) 2010-03-16 — — US disclosed
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INCORPORATED (US) 2009-04-16 — — US disclosed
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INCORPORATED (US) 2009-04-16 — — US disclosed
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 — — US disclosed
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 — — US disclosed
WO-2007115306-A2 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INC. (US) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS CLN6, NLN, CLTC IL1R1 4881/4885ALDH1A1 1938/4885ABCB1 476/4885
US-20120225845-A1 COMPOUNDS FOR DISEASES AND DISORDERS CLN6, NLN, CLTC IL1R1 4881/4885ALDH1A1 1938/4885ABCB1 476/4885
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction NCL, PSEN2, CCNO IL1R1 4718/4885ALDH1A1 2795/4885ABCB1 626/4885
US-20100184975-A1 COMPOUNDS FOR ALZHEIMBER'S DISEASE PSEN2, PSEN1, CLN6 IL1R1 4499/4885ALDH1A1 1225/4885ABCB1 462/4885
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE PSEN2, CHAT, PSEN1 IL1R1 4843/4885ALDH1A1 1321/4885ABCB1 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback